XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES (Tables)
 6 Months Ended
Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Disaggregation of Revenue
Revenues recognized under these agreements were as follows (in thousands):
Three Months Ended
June 30,		Six Months Ended
June 30,
2024202320242023
Revenue related to Kite agreement:
Recognition of license fee fixed consideration$— $1,110 $— $12,550 
Research services variable consideration— 121 — 989 
Total$— $1,231 $— $13,539 
Revenue related to Novartis agreement:
Recognition of upfront license fee$— $1,872 $— $9,568 
Research services— 554 — 2,613 
Total$— $2,426 $— $12,181 
Revenue related to Biogen agreement:
Recognition of license and other fixed consideration$— $1,535 $— $132,165 
Cost-sharing payments for research services, net variable consideration— 669 — 2,341 
Total$— $2,204 $— $134,506 
Revenue from other license agreements$356 $974 $837 $4,566 
Total revenue$356 $6,835 $837 $164,792